Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2017 Aug;116:159-177. doi: 10.1016/j.critrevonc.2017.05.010. Epub 2017 Jun 3.

Azacitidine in adult patients with acute myeloid leukemia.

Author information

1
Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: andre.schuh@uhn.ca.
2
Universitätsklinikum Ulm, Ulm, Germany.
3
3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute - Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Austria.
4
Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Parkville, Australia.
5
Hôpital Saint Louis, Institut Universitaire d'Hématologie, Paris, France.

Abstract

Azacitidine is recommended front-line treatment for older patients with acute myeloid leukemia (AML) who are not candidates for intensive treatment regimens, and was recently granted approval in the European Union for treatment of adult AML. Reviewed here is azacitidine experience in AML, including: mechanistic and pharmacokinetic data; safety and efficacy in controlled trials; treatment effects in AML subpopulations defined by disease characteristics; experience in unselected patients treated in the community setting; clinical outcomes relative to other approved AML therapies; and experience with azacitidine-based combination treatment regimens. Collectively, these data suggest that (a) azacitidine may prolong overall survival to a similar or greater extent than do other approved AML treatments, but with less toxicity, (b) azacitidine may be the preferred treatment option for older patients with unfavorable cytogenetics, and (c) experience and outcomes with azacitidine in the clinic are similar to those seen in clinical trials. Continued investigation of combination regimens on an azacitidine backbone is warranted.

KEYWORDS:

AML; Acute myeloid leukemia; Azacitidine; CC-486; Decitabine; Induction chemotherapy; Low-dose cytarabine

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center